Monoclonal Gammopathy of Undetermined Significance
"Monoclonal Gammopathy of Undetermined Significance" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia.
| Descriptor ID |
D008998
|
| MeSH Number(s) |
C15.378.147.542.640 C15.378.147.780.570 C20.683.460.640 C20.683.780.640
|
| Concept/Terms |
Monoclonal Gammopathy of Undetermined Significance- Monoclonal Gammopathy of Undetermined Significance
- Monoclonal Gammopathies, Benign
- Monoclonal Gammapathy of Undetermined Significance
- Benign Monoclonal Gammopathies
- Benign Monoclonal Gammopathy
- Monoclonal Gammopathy, Benign
- Monoclonal Gammapathies, Benign
- Benign Monoclonal Gammapathies
- Benign Monoclonal Gammapathy
- Monoclonal Gammapathy, Benign
|
Below are MeSH descriptors whose meaning is more general than "Monoclonal Gammopathy of Undetermined Significance".
Below are MeSH descriptors whose meaning is more specific than "Monoclonal Gammopathy of Undetermined Significance".
This graph shows the total number of publications written about "Monoclonal Gammopathy of Undetermined Significance" by people in this website by year, and whether "Monoclonal Gammopathy of Undetermined Significance" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
| 2025 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Monoclonal Gammopathy of Undetermined Significance" by people in Profiles.
-
Psychosocial and NF-?B Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial. Psychooncology. 2025 Jul; 34(7):e70216.
-
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
-
The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study. BMC Cancer. 2024 Feb 05; 24(1):174.
-
Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6. Blood Cancer J. 2022 04 13; 12(4):60.
-
When a Monoclonal Gammopathy Is Not Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-10.
-
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022 May; 9(5):e340-e349.
-
Kidney Transplantation in Patients With Monoclonal Gammopathy of Renal Significance (MGRS)-Associated Lesions: A Case Series. Am J Kidney Dis. 2022 02; 79(2):202-216.
-
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. Am J Hematol. 2021 07 01; 96(7):846-853.
-
Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment. Semin Ultrasound CT MR. 2021 Apr; 42(2):184-193.
-
Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120. Clin Cancer Res. 2020 11 15; 26(22):5814-5819.